Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

APG 157

Next Previous
Drug Profile

APG 157

Alternative Names: APG-157

Latest Information Update: 24 Sep 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Aveta Biomics
  • Class Antineoplastics
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Head and neck cancer
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Head and neck cancer; Oropharyngeal dysplasia; Squamous cell cancer
  • Phase I/II Glioblastoma

Most Recent Events

  • 24 Sep 2026 APG 157 receives Fast Track designation for Head and neck cancer [PO] (First-line therapy, Late-stage disease, Neoadjuvant therapy) in USA (Aveta Biomics pipeline, September 2026)
  • 24 Sep 2026 APG 157 receives Orphan Drug status for Head and neck cancer (First-line therapy, Late-stage disease) in USA (Aveta Biomics pipeline, September 2026)
  • 01 Jul 2026 Aveta Biomics plans a phase III trial for Squamous cell carcinoma (First-line therapy, Late-stage disease, Neoadjuvant therapy) (PO, Lozenge) in July 2026 (NCT07667296)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top